Yoseph Bornstein - Microbot Medical COFounder Director
| MBOT Stock | USD 0.99 0.01 1.02% |
Director
Mr. Yoseph Bornstein is Director of the Company. He is a cofounder of Microbot Israel and was a member of the Board of Directors since Microbot Israel was founded in November 2010. Mr. Bornstein founded Shizim Ltd., a life science holding group in October 2000 and has served as its president since then. Mr. Bornstein is the Chairman of GCP Clinical Studies Ltd., a provider of clinical research services and educational programs in Israel since January 2002. He is the Chairman of Biotis Ltd., a service company for the biopharmaceutical industry, since June 2000. In addition, he is the Chairman of Dolphin Medical Ltd., a service company for the medical device industry, since April 2012 and the Chairman of ASIS Enterprises B.B.G. Ltd., a business August 2007. In October 1992, Mr. Bornstein founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in 2000. Mr. Bornstein is also a founder of a number of other privately held lifescience companies. Mr. Bornstein served as the Biotechnology Committee Chairman of the Unites StatesIsrael Science Technology Commission from September 2002 to February 2005 as well as a consultant for USISTF from September 2002 to February 2005. He is also the founder of ILSIIsrael Life Science Industry Organization and ITTNIsrael Tech Transfer Organization. since 2016.
| Age | 65 |
| Tenure | 8 years |
| Address | 288 Grove Street, Braintree, MA, United States, 02184 |
| Phone | 781 875 3605 |
| Web | https://microbotmedical.com |
Latest Insider Transactions
| 2020-10-19 | Disposed of 4881 shares @ 7.94 | View | |
| 2020-10-05 | Disposed of 20000 shares @ 7.74 | View | |
| 2020-08-17 | Disposed of 15119 shares @ 10.19 | View | |
| 2018-01-09 | Disposed of 35000 shares @ 1.06 | View | |
| 2018-01-02 | Disposed of 42132 shares @ 1.01 | View | |
| 2017-12-27 | Disposed of 14257 shares @ 1.02 | View | |
| 2017-12-19 | Disposed of 32067 shares @ 1.03 | View | |
| 2017-12-12 | Disposed of 44159 shares @ 1.04 | View | |
| 2017-12-06 | Disposed of 15375 shares @ 1.05 | View | |
| 2017-11-28 | Disposed of 45000 shares @ 1.07 | View | |
| 2017-11-21 | Disposed of 45000 shares @ 1.21 | View | |
| 2017-10-24 | Disposed of 50000 shares @ 1.14 | View | |
| 2017-10-17 | Disposed of 50000 shares @ 1.16 | View |
Yoseph Bornstein Latest Insider Activity
Tracking and analyzing the buying and selling activities of Yoseph Bornstein against Microbot Medical stock is an integral part of due diligence when investing in Microbot Medical. Yoseph Bornstein insider activity provides valuable insight into whether Microbot Medical is net buyers or sellers over its current business cycle. Note, Microbot Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Microbot Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Yoseph Bornstein over three months ago Disposition of 45000 shares by Yoseph Bornstein of Microbot Medical at 1.0733 subject to Rule 16b-3 | ||
Yoseph Bornstein over three months ago Disposition of 32067 shares by Yoseph Bornstein of Microbot Medical at 1.03 subject to Rule 16b-3 | ||
Yoseph Bornstein over three months ago Disposition of 44159 shares by Yoseph Bornstein of Microbot Medical at 1.0372 subject to Rule 16b-3 |
Microbot Medical Management Efficiency
The company has return on total asset (ROA) of (0.6488) % which means that it has lost $0.6488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3446) %, meaning that it created substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.23 in 2024. Return On Capital Employed is likely to gain to -2.06 in 2024. Total Current Liabilities is likely to gain to about 4.8 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 7.9 M in 2024.Similar Executives
| Found 4 records | DIRECTOR Age | ||
| Chris Paalman | Healthcare Triangle | N/A | |
| Sarah Wallace | Nutex Health | N/A | |
| Alfred Lim | EUDA Health Holdings | 72 | |
| LaTanya Brackens | Nutex Health | N/A | |
Management Performance
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.65 |
Microbot Medical Leadership Team
Elected by the shareholders, the Microbot Medical's board of directors comprises two types of representatives: Microbot Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Microbot. The board's role is to monitor Microbot Medical's management team and ensure that shareholders' interests are well served. Microbot Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Microbot Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rachel Vaknin, Chief Officer | ||
| Harel Gadot, Chairman of the Board and Presidentident, CEO | ||
| Yoseph Bornstein, COFounder Director | ||
| Eyal MD, Chief Board | ||
| MSc MBA, CTO Israel | ||
| Pr DSc, Scientific CoFounder | ||
| Juan DiazCartelle, Chief Officer |
Microbot Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Microbot Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.65 | ||||
| Current Valuation | 12.35 M | ||||
| Shares Outstanding | 16.93 M | ||||
| Shares Owned By Insiders | 1.42 % | ||||
| Shares Owned By Institutions | 7.46 % | ||||
| Number Of Shares Shorted | 565.98 K | ||||
| Price To Earning | (3.42) X | ||||
| Price To Book | 4.36 X | ||||
| EBITDA | (10.63 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.